Ascentage Pharma Group International ADR - W/I (AAPGV)
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 17.380
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 18.000
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- Polish Emitent · Jan 26 at 01:20 PM
SOPHARMA AD - Notification from Ivan Badinski under Regulation 596/2014 for exercise of rights for issue of warrants with ISIN № BG4000002262
- Unusual Whales · Dec 9, 2025 at 12:47 AM
Ascentage Pharma presents four-year follow-up data on Olverembatinib for TKI-resistant/intolerant CML-CP at ASH 2025, reaffirming long-term efficacy and safety in a registrational Phase II study.
- Unusual Whales · Dec 6, 2025 at 03:15 PM
Ascentage Pharma presents Phase II China study on Lisaftoclax at ASH Annual Meeting, supporting NDA approval by NMPA in July 2025.
- Tip Ranks · Nov 25, 2025 at 01:30 PM
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment
- Tip Ranks · Aug 20, 2025 at 11:08 PM
Ascentage Pharma Reports Revenue Decline Amidst Strategic Drug Approvals
- StockTitan · Aug 17, 2025 at 11:30 PM
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA | AAPG Stock News
